SIOPEN

  • International Society of Paediatric Oncology Europe Neuroblastoma

What is a clinical trial?

To improve our knowledge about how best to treat patients with neuroblastoma, SIOPEN brings together doctors from across Europe and beyond. Patients treated on SIOPEN protocols will then receive the same treatment regardless of which SIOPEN centre they are treated at. Actual treatment recommendations will depend on the disease risk group and other factors. By collecting information from many different centres, it is possible to see how well different treatments have worked and gain knowledge about how best to treat patients in the future.

Some studies include a randomisation - where one set of treatments are compared against another in order to determine which works better or has fewer side effects. The randomisation means that each patient joining the study is allocated by chance to one treatment or the other, rather than this being decided by your doctor. The results for both groups in the trial are watched closely by an independent monitoring committee. They can stop the trial at any time if one of the treatments is shown to be better than the other.

More information on clinical trials can be found here:

ITCC

SIOPEN meetings

Forthcoming meetings:

Berlin (Germany) AGM

25-27 October 2017 

click for more information

SIOPEN

SIOPEN Verein zur Foderung der Neuroblastomforschung is an Association registered in Austria and recognised as a non-profit organisation according to the Austrian Federal Tax Code (Bundesabgabenordnung BAO). Registration number ZVR 396592912. The SIOPEN Association was officially established on 20 January 2009.

This website makes use of stock photography and images do not represent particular individuals treated by SIOPEN institutions.